Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - Hepion Pharmaceuticals, Inc. | a2230877z10-q.htm |
| EX-32.2 - EX-32.2 - Hepion Pharmaceuticals, Inc. | a2230877zex-32_2.htm |
| EX-31.2 - EX-31.2 - Hepion Pharmaceuticals, Inc. | a2230877zex-31_2.htm |
| EX-31.1 - EX-31.1 - Hepion Pharmaceuticals, Inc. | a2230877zex-31_1.htm |
QuickLinks -- Click here to rapidly navigate through this document
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
CONTRAVIR PHARMACEUTICALS, INC.
FORM 10-Q FOR THE QUARTER ENDED DECEMBER 31, 2016
PURSUANT TO 18 U.S.C. SECTION 1350, AS
ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I am the Chief Executive Officer of ContraVir Pharmaceuticals, Inc., a Delaware corporation (the "Company"). I am delivering this certificate in connection with the Form 10-Q of the Company for the quarter ended December 31, 2016 and filed with the Securities and Exchange Commission ("Form 10-Q").
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I hereby certify that, to the best of my knowledge, the Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: February 14, 2017 | /s/ JAMES SAPIRSTEIN James Sapirstein Chief Executive Officer and Director (Principal Executive Officer) |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER CONTRAVIR PHARMACEUTICALS, INC. FORM 10-Q FOR THE QUARTER ENDED DECEMBER 31, 2016 PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002